

Dzintars Gotham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7352565/publications.pdf>

Version: 2024-02-01

29
papers

717
citations

516561

16
h-index

610775

24
g-index

31
all docs

31
docs citations

31
times ranked

1072
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C. <i>Journal of Virus Eradication</i> , 2016, 2, 28-40.	0.3	60
2	Estimated costs of production and potential prices for the WHO Essential Medicines List. <i>BMJ Global Health</i> , 2018, 3, e000571.	2.0	55
3	Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment. <i>BMJ Open</i> , 2016, 6, e009586.	0.8	49
4	Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 527-540.	0.7	48
5	Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?. <i>Journal of Virus Eradication</i> , 2018, 4, 72-79.	0.3	44
6	Production costs and potential prices for biosimilars of human insulin and insulin analogues. <i>BMJ Global Health</i> , 2018, 3, e000850.	2.0	42
7	Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C. <i>Journal of Virus Eradication</i> , 2016, 2, 28-31.	0.3	39
8	Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis. <i>BMJ Open</i> , 2017, 7, e011965.	0.8	30
9	Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials. <i>Aids</i> , 2020, 34, 2259-2268.	1.0	30
10	Candidates for inclusion in a universal antiretroviral regimen. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 324-333.	1.5	30
11	Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States. <i>Health Policy</i> , 2021, 125, 296-306.	1.4	29
12	Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. <i>Journal of Virus Eradication</i> , 2015, 1, 103-110.	0.3	28
13	Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries. <i>Journal of Virus Eradication</i> , 2020, 6, 100001.	0.3	23
14	Estimated generic prices for novel treatments for drug-resistant tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw522.	1.3	19
15	Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. <i>Journal of Virus Eradication</i> , 2015, 1, 103-10.	0.3	16
16	How the MDGs gave up on measuring access to medicines. <i>The Lancet Global Health</i> , 2016, 4, e296-e297.	2.9	14
17	Quantifying changes in global health inequality: the Gini and Slope Inequality Indices applied to the Global Burden of Disease data, 1990-2017. <i>BMJ Global Health</i> , 2019, 4, e001500.	2.0	14
18	Public investments in the clinical development of bedaquiline. <i>PLoS ONE</i> , 2020, 15, e0239118.	1.1	14

#	ARTICLE	IF	CITATIONS
19	Public investments in the development of GeneXpert molecular diagnostic technology. PLoS ONE, 2021, 16, e0256883.	1.1	12
20	Global health equity in United Kingdom university research: a landscape of current policies and practices. Health Research Policy and Systems, 2016, 14, 76.	1.1	11
21	Estimation of cost-based prices for injectable medicines in the WHO Essential Medicines List. BMJ Open, 2019, 9, e027780.	0.8	9
22	Global health research and education at medical faculties in Germany. PLoS ONE, 2020, 15, e0231302.	1.1	8
23	Open letter to the candidates for Director-General of WHO: will you support a patient-centred R&D agreement?. The Lancet Global Health, 2017, 5, e135-e136.	2.9	6
24	Drug prices threaten the NHS. Lancet, The, 2016, 388, 2603-2604.	6.3	0
25	Cell line access to revolutionize the biosimilars market. F1000Research, 2018, 7, 537.	0.8	0
26	Public investments in the clinical development of bedaquiline. , 2020, 15, e0239118.		0
27	Public investments in the clinical development of bedaquiline. , 2020, 15, e0239118.		0
28	Public investments in the clinical development of bedaquiline. , 2020, 15, e0239118.		0
29	Public investments in the clinical development of bedaquiline. , 2020, 15, e0239118.		0